Highest-materiality recent filing
Definium Therapeutics prices $805M public offering of 20.6M shares at $34 each, upsized from $700M
Offering of 20,588,236 common shares at $34.00 per share, with full exercise of underwriters' 30-day option for additional 3,088,235 shares.
Definium Therapeutics reports positive Phase 3 results for DT120 ODT in major depressive disorder
Study met primary endpoint with 8.1-point MADRS placebo-adjusted improvement at Week 6 (p<0.0001)
Cash and investments $373.4M as of March 31, 2026; expected to fund operations into 2028.
Definium provides DT120 ODT clinical updates; MDD/GAD readouts in 2H 2026, expansion into PTSD
MDD Emerge trial topline data on track for late 2Q 2026; 149 participants randomized 1:1 to DT120 100 µg or placebo.
Definium Therapeutics FY2025 cash $411.6M; Phase 3 MDD trial fully enrolled, topline late Q2 2026
Cash, cash equivalents and investments of $411.6M as of Dec 31, 2025, up from $273.7M in 2024; expected to fund operations into 2028.
MindMed rebrands to Definium Therapeutics; $412M cash; three Phase 3 readouts in 2026
Preliminary cash and investments ~$412M as of Dec 31, 2025.
MindMed Q3 cash $209M, raises $242.8M; MM120 Phase 3 GAD/MDD readouts on track for 2026
Cash, cash equivalents and investments of $209.1M at Sept 30, 2025; net proceeds of $242.8M from Oct 31 offering extend runway into 2028.
Issued 18,375,000 common shares at $12.25 per share; underwriters exercised option for additional 2,756,250 shares.
MindMed publishes Phase 2b results for MM120 (LSD) in GAD in JAMA; 100 µg dose meets endpoints
MM120 100 µg showed 7.6-point greater HAM-A reduction vs placebo at Week 4 (p<0.0004, d=0.88); 65% response rate, 48% remission at Week 12.
MindMed Q2 2025 net loss widens to $42.7M; cash $237.9M; Phase 3 trials on track
Net loss of $42.7M in Q2 2025 vs $5.9M in Q2 2024, driven by higher R&D and warrant fair value changes.
MindMed appoints Brandi Roberts as CFO effective June 2, 2025; inducement awards granted
Roberts previously CFO of Longboard Pharmaceuticals, led IPO and $2.6B Lundbeck acquisition.
MindMed reports Q1 cash $245.5M; Phase 3 trials on track for 2026 topline data
Cash and investments $245.5M at March 31, 2025; runway into 2027 and at least 12 months beyond first Phase 3 readout.
MindMed amends credit facility, gets $42M new term loan; total capacity up to $120M
Restated credit facility provides up to $120M in term loans; $42M funded immediately to refinance existing debt.
MindMed reports $273.7M cash, advances MM120 Phase 3 trials in GAD and MDD
Cash and equivalents $273.7M at Dec 31, 2024 vs $99.7M a year ago; raised ~$250M in 2024.
MindMed doses first patient in Phase 3 Panorama study of MM120 for GAD; data H2 2026
First patient dosed in Panorama, second Phase 3 study of MM120 ODT (LSD) for generalized anxiety disorder.
MindMed terminates Executive President Miri Halperin Wernli without cause, effective Feb 28, 2025
Employment terminated without cause; effective February 28, 2025.
MindMed doses first patient in Phase 3 Voyage study of MM120 for GAD
First-ever Phase 3 study of lysergide D-tartrate (LSD) for GAD; primary endpoint HAM-A change at week 12 vs placebo.
MindMed Q3 net loss $13.7M; cash $295.3M; Phase 3 Voyage on track for Q4 2024
Net loss $13.7M vs $17.9M a year ago; R&D expenses $17.2M (up $4.0M YoY) on MM120/MM402 programs.
MindMed exchanges 8M common shares for pre-funded warrants at $0.001 exercise price
Exchanged 8,000,000 common shares held by Commodore Capital and Deep Track Biotechnology for pre-funded warrants to purchase 8,000,000 common shares at $0.001 each.
MindMed Q2 net loss narrows to $5.9M; cash at $243M to fund Phase 3 in GAD
Net loss of $5.9 million, down from $29.1 million in Q2 2023, primarily due to warrant fair value changes.
MindMed prices $75M public offering of common shares and pre-funded warrants; cash position $243.1M
Underwritten public offering of 9,285,511 common shares at $7.00/share and 1,428,775 pre-funded warrants at $6.999/warrant.
MindMed enters $150M ATM equity program with Leerink Partners, terminates prior ATM
New at-the-market sales agreement with Leerink Partners LLC authorizes sale of up to $150M in common shares.
MindMed reaches alignment with FDA on Phase 3 plan for MM120 in GAD
Constructive End-of-Phase 2 meeting with FDA; aligned on Phase 3 requirements for MM120 (LSD D-tartrate) in generalized anxiety disorder.
MindMed reports Q1 net loss $54.4M; MM120 GAD trial hits key endpoint, FDA Breakthrough Therapy
Net loss $54.4M Q1'24 (vs $24.8M); includes $27.7M warrant fair value change. R&D $11.7M, G&A $10.5M.
MindMed prices $175M combined offering of common shares at $6.00 each
Underwritten offering of 16,666,667 common shares at $6.00 per share with net proceeds of ~$93.8M.
FDA breakthrough designation for MM120 (lysergide d-tartrate) to treat generalized anxiety disorder.
MindMed reports Phase 2b topline data for MM120 in GAD; gets FDA Breakthrough Therapy Designation
Phase 2b trial of MM120 (LSD) for Generalized Anxiety Disorder: full topline data released on March 7, 2024.
MindMed reports FY2023 net loss $95.7M; Phase2b MM120 shows 7.6-point HAM-A reduction for GAD
Cash and equivalents $99.7M vs $142.1M at Dec 2022; expected to fund operations into 2026.
MindMed provides 2024 outlook; GAD Phase 2b showed 7.6-point HAM-A reduction, ADHD trial failed
MM-120 100µg GAD: 7.6 HAM-A reduction vs placebo (p<0.0004, effect size 0.88); 78% response, 50% remission.
MindMed Phase 2b MM-120 in GAD meets primary endpoint, 7.6-point HAM-A improvement vs placebo
MM-120 100 µg achieved 21.3-point HAM-A reduction vs 13.7 placebo (p=0.0004, Cohen's d=0.88) at Week 4 after single dose.
MindMed Q3 net loss $17.9M; cash $117.7M; Phase 2b GAD topline expected Q4 2023
Cash and cash equivalents $117.7M at Sept 30, 2023; expected to fund operations into 2026.
MindMed enters up to $50M term loan with K2 HealthVentures; first tranche of $15M funded
Loan Agreement with K2 HealthVentures provides term loans up to $50M; initial $15M drawn on Aug 11, 2023.
MindMed Q2 net loss $29.1M, cash $116.9M; MM-120 GAD topline readout on track for Q4 2023
Net loss of $29.1M in Q2 2023 vs $17.0M in Q2 2022; R&D spend rose to $14.8M ($9.3M prior).
MindMed annual meeting adjourned; potential Nasdaq delisting risk from quorum issue
2023 annual general meeting on June 15 failed due to lack of 33 1/3% quorum; reconvened for June 21 at 10 a.m. ET.
MindMed adjourns annual meeting due to lack of quorum; accuses FCM of deliberate obstruction
Annual meeting on June 15, 2023 adjourned without business due to absence of required 33⅓% quorum.
had appointed Brandi L. Roberts as Chief Financial Officer, effective as of June 2, 2025 (the “Effective Date”).
Carrie Liao, the Company’s Chief Accounting Officer, will no longer serve as the Company’s principal financial officer and principal accounting officer.
On January 10, 2025, Mind Medicine (MindMed) Inc. (the "Company") notified Miri Halperin Wernli, the Company's Executive President, that it was terminating her employment without cause, effective February 28, 2025, as the Company centralizes its management team in the United States to enhance collaboration and alignment with its strategic goals.
On April 15, 2023, after extensive consideration and discussion with the Board of Directors (the “ Board ”) of Mind Medicine (MindMed) Inc. (the “ Company ”), Brigid A. Makes provided notice to the Board of her decision not to stand for re-election at the Company’s 2023 annual general meeting of shareholders (the “ Annual Meeting ”).
On August 11, 2022, Miri Halperin Wernli, M.D. notified the Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (the “Company”) that she is resigning from the Board as of August 11, 2022.
On August 11, 2022, the Board appointed Suzanne Bruhn, Ph.D. to the Board, filling the vacancy left by the resignation of Dr. Halperin Wernli, effective immediately.
On May 23, 2022, Mind Medicine (MindMed) Inc. (the “Company”) announced the appointment of Schond Greenway as the Company’s Chief Financial Officer, effective May 23, 2022
On March 25, 2022, David D. Guebert and the Company agreed to a separation from the Company with Mr. Guebert’s last day of employment on March 31, 2022.
On March 24, 2022, Sarah Y. Vinson, M.D. notified the Board of Directors (the “Board”) of Mind Medicine (MindMed) Inc. (the “Company”) that she will not stand for re-election as a director of the Company at its 2022 Annual Meeting
On January 5, 2022, Mr. Stephen Hurst, a member of the board of directors (the “Board”) of Mind Medicine (MindMed) Inc. (the “Company”), notified the Board of his decision to resign from the Board, effective immediately.
Max materiality 0.90 · Median 0.65 · Most common event other_material